A/S Genmab Purchases 1,052,806 Shares of Merus (NASDAQ:MRUS) Stock

31 Dec 2025, 00:12 by Kim Johansen · The Markets Daily

Merus N.V. (NASDAQ:MRUS – Get Free Report) major shareholder A/S Genmab acquired 1,052,806 shares of Merus stock in a transaction that occurred on Monday, December 29th. The shares were bought at an average cost of $97.00 per share, with a total value of $102,122,182.00. Following the transaction, the insider owned 73,884,293 shares in the company, valued at $7,166,776,421. This represents a 1.45% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

A/S Genmab also recently made the following trade(s):

On Friday, December 26th, A/S Genmab acquired 2,978 shares of Merus stock. The shares were bought at an average price of $97.00 per share, for a total transaction of $288,866.00.
On Friday, December 26th, A/S Genmab bought 142,610 shares of Merus stock. The stock was purchased at an average cost of $97.00 per share, for a total transaction of $13,833,170.00.
On Wednesday, December 24th, A/S Genmab purchased 96,082 shares of Merus stock. The stock was acquired at an average price of $97.00 per share, for a total transaction of $9,319,954.00.
On Tuesday, December 23rd, A/S Genmab acquired 561,042 shares of Merus stock. The shares were bought at an average cost of $97.00 per share, for a total transaction of $54,421,074.00.
On Monday, December 22nd, A/S Genmab bought 15,710 shares of Merus stock. The stock was purchased at an average cost of $97.00 per share, with a total value of $1,523,870.00.
On Friday, December 19th, A/S Genmab acquired 66,264 shares of Merus stock. The shares were bought at an average cost of $97.00 per share, with a total value of $6,427,608.00.
On Thursday, December 18th, A/S Genmab acquired 212,177 shares of Merus stock. The shares were bought at an average cost of $97.00 per share, with a total value of $20,581,169.00.
On Wednesday, December 17th, A/S Genmab bought 150,795 shares of Merus stock. The stock was acquired at an average cost of $97.00 per share, with a total value of $14,627,115.00.
On Tuesday, December 16th, A/S Genmab acquired 120,752 shares of Merus stock. The shares were bought at an average cost of $97.00 per share, for a total transaction of $11,712,944.00.

Merus Stock Performance

MRUS stock traded down $6.92 during mid-day trading on Tuesday, reaching $90.00. 2,728,600 shares of the stock traded hands, compared to its average volume of 1,265,390. Merus N.V. has a one year low of $33.19 and a one year high of $97.14. The stock has a market capitalization of $6.83 billion, a PE ratio of -16.98 and a beta of 1.06. The business has a 50-day moving average price of $95.78 and a two-hundred day moving average price of $77.75.

Merus News Roundup

Here are the key news stories impacting Merus this week:

Positive Sentiment: Major shareholder A/S Genmab executed multiple large purchases of Merus shares across Dec. 16–26 (totaling well over 800,000 shares at ~$97 each), increasing its stake and showing clear insider demand that can be read as confidence in the deal value. SEC Ownership Filing
Positive Sentiment: Additional filings and reporting highlight several discrete purchases by Genmab (e.g., a 15,710‑share buy disclosed Dec. 22), reinforcing the pattern of insider accumulation ahead of the corporate action. InsiderTrades Article
Neutral Sentiment: Trading in MRUS was temporarily halted with the stated reason “News pending,” which often precedes material corporate disclosures and contributes to sudden intraday volatility while the market digests the announcement. (Trade‑halt notice from exchange filings/news wires.)
Neutral Sentiment: Analyst coverage remains mixed-to-neutral (consensus “Hold” and a roughly mid‑$90s target), so broker commentary is unlikely to change the immediate direction absent clarity on deal consideration and timing. MarketBeat MRUS Coverage
Negative Sentiment: Merus confirmed completion of the transaction with Genmab and that Merus will delist from Nasdaq — a material corporate event that typically ends public trading of the ticker and can trigger forced selling, uncertainty over timing and consideration, and repricing of the remaining float. That delisting/transaction announcement is the most direct reason for the stock’s downward move today. TipRanks: Merus Completes Genmab Acquisition

Institutional Trading of Merus

A number of institutional investors have recently bought and sold shares of MRUS. Quarry LP purchased a new position in shares of Merus during the third quarter worth about $42,000. Farther Finance Advisors LLC lifted its stake in shares of Merus by 10,400.0% in the third quarter. Farther Finance Advisors LLC now owns 525 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 520 shares during the period. Longfellow Investment Management Co. LLC acquired a new stake in shares of Merus during the 3rd quarter valued at approximately $75,000. CWM LLC grew its holdings in shares of Merus by 299.0% in the 2nd quarter. CWM LLC now owns 802 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 601 shares during the period. Finally, Quantbot Technologies LP purchased a new position in shares of Merus in the third quarter valued at $114,000. 96.14% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Leerink Partnrs lowered Merus from a “strong-buy” rating to a “hold” rating in a research report on Sunday, October 5th. HC Wainwright cut shares of Merus from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $135.00 to $97.00 in a report on Monday, September 29th. UBS Group lowered Merus from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $72.00 to $97.00 in a research report on Tuesday, September 30th. Leerink Partners restated a “market perform” rating and set a $97.00 target price (up from $95.00) on shares of Merus in a research report on Monday, October 6th. Finally, Wells Fargo & Company restated an “equal weight” rating and set a $97.00 price objective (up from $95.00) on shares of Merus in a research report on Monday, September 29th. Three investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Merus has an average rating of “Hold” and a consensus target price of $93.56.

Check Out Our Latest Report on MRUS

Merus Company Profile

(Get Free Report)

Merus NV is a clinical-stage immuno-oncology company focused on the discovery and development of bispecific antibody therapeutics for the treatment of cancer. Utilizing its proprietary Biclonics® platform, Merus engineers fully human bispecific antibodies designed to engage immune cells and tumor targets simultaneously. The company’s research efforts are aimed at creating novel therapies with optimized potency, selectivity and safety profiles.